Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Food and Healthcare Press Releases Wednesday December 20, 2017 08:20
SINGAPORE--20 Dec--PRNewswire/InfoQuest
  • Proceeds to be used to further develop Tessa's advanced solid tumor immunotherapy pipeline
  • Funding round reinforces Tessa's position as an emerging leader in cellular immunotherapy with the vision of bringing transformational change to cancer therapy

Tessa Therapeutics , an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, today announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.

Andrew Khoo, co-founder and CEO of Tessa Therapeutics, commented: "We are very pleased with the success in this financing round which validates our work and continued progress in the development of Tessa's Virus Specific T cell platform technology and clinical pipeline. Tessa plans to expand its global presence and advance next generation cellular therapies targeting a wide range of cancer indications."

Tessa will use the proceeds from this funding round to further advance its clinical pipeline and to bring new therapies, based on the company's Virus Specific T cell (VST) platform, into clinical trials.

Tessa's VST technology is showing compelling results in the treatment of solid tumors. The company is currently conducting a multi-center Phase III trial targeting nasopharyngeal cancer and a Phase I trial targeting cervical cancer and oropharyngeal cancer.   In recent years, Tessa has built robust operational and supply chain capabilities allowing the company to effectively deliver autologous T cell therapy treatments to a large patient pool internationally.

Virus-Specific T cells are produced through a selective expansion process that gives them the ability to infiltrate and survive in solid tumors long enough to attack and destroy them from within, a key differentiator to other cell therapies. Tessa's VSTs migrate to the tumor site and kill cancer cells with precision leaving healthy cells unharmed, leading to high treatment efficacy and safety.

Contacts
Media:
Tessa Therapeutics
Brunswick Group
Will Carnwath, Ben Fry
TessaTherapeutics@brunswickgroup.com
+65-6426-8188
Investor Relations:
Tessa Therapeutics
Trout Group
Pete Rahmer
prahmer@troutgroup.com
+1-646-378-2973
About Tessa Therapeutics

Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body's potent anti-viral immune response to recognize and kill cancer cells. Tessa's core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa's lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world's largest Phase III T cell immunotherapy trial for any cancer indication. The company has built up robust operational and supply chain capabilities to successfully deliver autologous T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled the company to create a fully-integrated approach to the treatment of cancer with immunotherapy.

For more information on Tessa, please visit www.tessatherapeutics.com
About Temasek

Incorporated in 1974, Temasek is an investment company headquartered in Singapore. Supported by 10 offices internationally, Temasek owns a S$275 billion (US$197b) portfolio as at 31 March 2017, mainly in Singapore and the rest of Asia.

Our portfolio covers a broad spectrum of industries: financial services; telecommunications, media & technology; transportation & industrials; consumer & real estate; life sciences & agribusiness; as well as energy & resources. Our investment activities are guided by four investment themes and the long-term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions.

For more information on Temasek, please visit www.temasek.com.sg

Latest Press Release

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Related Topics